News
SNY
44.25
+0.32%
0.14
On Friday, FDA Granted Accelerated Approval To Sanofi's Tzield (Teplizumab-mzwv) To Delay Decline In Endogenous (Own) Insulin Production In Children Aged 8 To 17 Years Recently Diagnosed With Stage 3 Type 1 Diabetes
Benzinga · 1h ago
Weekly Report: what happened at SNY last week (0608-0612)?
Weekly Report · 2h ago
Deutsche Bank Keeps Their Buy Rating on Sanofi (SNYNF)
TipRanks · 4h ago
Sanofi type 1 diabetes therapy Tzield approved in U.S. for stage 3 of the disease
Seeking Alpha · 1d ago
FDA Grants Accelerated Approval To Sanofi's Tzield For Children With Stage 3 Type 1 Diabetes
NASDAQ · 2d ago
FDA grants accelerated approval to Sanofi Tzield for newly diagnosed stage 3 type 1 diabetes in children 8-17
PUBT · 2d ago
PRESS RELEASE: SANOFI’S TZIELD APPROVED IN THE US AS THE FIRST DISEASE-MODIFYING THERAPY FOR PATIENTS RECENTLY DIAGNOSED WITH STAGE 3 TYPE 1 DIABETES
Reuters · 2d ago
FDA: TZIELD HAS A BOXED WARNING - WEBSITE
Reuters · 2d ago
Dianthus’ new CAPTIVATE responder rate beat expectations, says Raymond James
TipRanks · 2d ago
Sanofi Expands Global Employee Share Plan with 2026 Offering
TipRanks · 2d ago
Sanofi launches 2026 employee share plan with EUR 59.87 subscription price, 20% discount
PUBT · 2d ago
Weekly Buzz: GH, LLY Gain FDA Nod; TEVA, GSK, Lead M&A Wave; ZEAL, LLY Post Strong Data
NASDAQ · 2d ago
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position: Analyst
Benzinga · 3d ago
Dianthus price target raised to $132 from $110 at Jefferies
TipRanks · 4d ago
Midday Fly By: SpaceX IPO oversubscribed, Chewy reports in-line Q1
TipRanks · 4d ago
Buy Dianthus on weakness amid ‘overdone’ selloff, says H.C. Wainwright
TipRanks · 4d ago
Video: Cracker Barrel advances after beat and raise report
TipRanks · 4d ago
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
NASDAQ · 4d ago
Stifel says Sanofi stopping MOBILIZE study potentially positive for Dianthus
TipRanks · 5d ago
Dianthus drops as Sanofi halts late-stage trial for CIDP therapy on efficacy concerns
Seeking Alpha · 5d ago
More
Webull provides a variety of real-time SNY stock news. You can receive the latest news about Sanofi FR through multiple platforms. This information may help you make smarter investment decisions.
About SNY
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.